Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Genitourinary 1

Conditions

Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thymus Neoplasms 1Thymoma 1Ovarian Neoplasms 1Mesothelioma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 8Nivolumab 3tislelizumab 2spartalizumab 2SS1(dsFv)PE38 2Ipilimumab 2fludarabine phosphate 1fludarabine 1epacadostat 1entinostat 1bosutinib 1atezolizumab 1aldesleukin 1Quality of Life 1Polymerase Chain Reaction 1Platinum 1Pemetrexed 1Patient Reported Outcome Measures 1Paclitaxel 1Molecular Diagnostic Techniques 1Microarray Analysis 1Interleukin-2 1Immunotherapy 1Immunoenzyme Techniques 1Hyperthermic Intraperitoneal Chemotherapy 1Gene Expression Profiling 1Gemcitabine 1Flow Cytometry 1Fentanyl 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × bosutinib × Other solid neoplasm × Clear all
NCT03023319 2022-06-14

Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors

Augusta University

Phase 1 Completed
6 enrolled
GenitourinaryGynecologicOther solid neoplasmThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Mesothelioma, Ovarian Neoplasms, Thymoma, Thymus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡